Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies
The introduction of tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia vastly improving the prognosis and clinical outcome of most patients. It was estimated that approximately 40–50 % of patients treated with imatinib will require treatment with a second-generat...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924002980 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037717109309440 |
|---|---|
| author | Tomasz Sacha Katarzyna Krawczyk |
| author_facet | Tomasz Sacha Katarzyna Krawczyk |
| author_sort | Tomasz Sacha |
| collection | DOAJ |
| description | The introduction of tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia vastly improving the prognosis and clinical outcome of most patients. It was estimated that approximately 40–50 % of patients treated with imatinib will require treatment with a second-generation or third-generation tyrosine kinase inhibitor to achieve an optimal response. The treatment duration, increased patient survival, and aging of the population receiving tyrosine kinase inhibitors raise concerns as to long-term toxicities, such as an elevated cardiovascular risk and a higher rate of comorbidities. Ponatinib is a highly potent third-generation tyrosine kinase inhibitor that was shown to be effective in patients with a wide range of ABL mutations, including T315I. The use of ponatinib is associated with significant vascular toxicity, including peripheral arterial occlusive disease, ischemic heart disease, cerebrovascular accidents, and venous thromboembolism. This review discusses the vascular toxicity of ponatinib and presents a comprehensive panel of tests for the evaluation of patients requiring ponatinib therapy. Moreover, the management of patients with cardiovascular risk factors who receive ponatinib is discussed. Finally, the strategy for establishing the optimal dose of ponatinib in patients with chronic myeloid leukemia is described. |
| format | Article |
| id | doaj-art-0d7d3f78a0ab48f5bfca4f458c7f95b5 |
| institution | DOAJ |
| issn | 2531-1379 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-0d7d3f78a0ab48f5bfca4f458c7f95b52025-08-20T02:56:47ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-01-0147110367510.1016/j.htct.2024.04.124Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategiesTomasz Sacha0Katarzyna Krawczyk1Corresponding author at: Department of Hematology, Jagiellonian University Medical College, ul. Kopernika 17, 31-501 Kraków, Poland.; Jagiellonian University Medical College, Kopernika, Kraków, PolandJagiellonian University Medical College, Kopernika, Kraków, PolandThe introduction of tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia vastly improving the prognosis and clinical outcome of most patients. It was estimated that approximately 40–50 % of patients treated with imatinib will require treatment with a second-generation or third-generation tyrosine kinase inhibitor to achieve an optimal response. The treatment duration, increased patient survival, and aging of the population receiving tyrosine kinase inhibitors raise concerns as to long-term toxicities, such as an elevated cardiovascular risk and a higher rate of comorbidities. Ponatinib is a highly potent third-generation tyrosine kinase inhibitor that was shown to be effective in patients with a wide range of ABL mutations, including T315I. The use of ponatinib is associated with significant vascular toxicity, including peripheral arterial occlusive disease, ischemic heart disease, cerebrovascular accidents, and venous thromboembolism. This review discusses the vascular toxicity of ponatinib and presents a comprehensive panel of tests for the evaluation of patients requiring ponatinib therapy. Moreover, the management of patients with cardiovascular risk factors who receive ponatinib is discussed. Finally, the strategy for establishing the optimal dose of ponatinib in patients with chronic myeloid leukemia is described.http://www.sciencedirect.com/science/article/pii/S2531137924002980PonatinibChronic myeloid leukemiaTyrosine kinase inhibitorCardiovascular riskManagement strategy |
| spellingShingle | Tomasz Sacha Katarzyna Krawczyk Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies Hematology, Transfusion and Cell Therapy Ponatinib Chronic myeloid leukemia Tyrosine kinase inhibitor Cardiovascular risk Management strategy |
| title | Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies |
| title_full | Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies |
| title_fullStr | Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies |
| title_full_unstemmed | Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies |
| title_short | Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies |
| title_sort | ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk a review of management strategies |
| topic | Ponatinib Chronic myeloid leukemia Tyrosine kinase inhibitor Cardiovascular risk Management strategy |
| url | http://www.sciencedirect.com/science/article/pii/S2531137924002980 |
| work_keys_str_mv | AT tomaszsacha ponatinibinthetreatmentofpatientswithchronicmyeloidleukemiaandincreasedcardiovascularriskareviewofmanagementstrategies AT katarzynakrawczyk ponatinibinthetreatmentofpatientswithchronicmyeloidleukemiaandincreasedcardiovascularriskareviewofmanagementstrategies |